Stereoselective transport and uptake of propranolol across human intestinal Caco-2 cell monolayers

Chirality

Volumn 22, Issue 3, 2010, Pages 361-368

  Wang, Yi ^a   Cao, Jiang ^b   Wang, Xiaodan ^a   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

adrenoceptor blocker; Accumulation; Apparent permeability coefficients; Enantiomers; HPLC; Inhibitor; Km; Vmax

Indexed keywords

CIMETIDINE; CYCLOSPORIN A; INDOMETACIN; OUABAIN; PROPRANOLOL; PROTEIN INHIBITOR; VERAPAMIL;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONTROLLED STUDY; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTESTINE CELL; PERMEABILITY; PH; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; HUMANS; INTESTINAL MUCOSA; INTESTINES; MEMBRANE POTENTIALS; P-GLYCOPROTEIN; PROPRANOLOL; SURFACE-ACTIVE AGENTS; SUS SCROFA; SWINE;

EID: 75849163801     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20753     Document Type: Article

References (45)

1. Howe R, Shanks RG. Optical isomers of propranolol. Nature 1966;210: 1336-1338.
2. Gilmore DA, Gal J, Gerber JG, Nies AS. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992;261:1181-1186.
3. Silber B, Holford NH, Riegelman S. Stereoselective disposition and glucuronidation of propranolol in humans. J Pharm Sci 1982;71:699-704.
4. Wilson AG, Brooke OG, Lloyd HJ, Robinson BF. Mechanism of action of beta-adrenergic receptor blocking agents in angina pectoris: comparison of action of propranolol with dexpropranolol and practolol. Br Med J 1969;4:399-401.
5. Egginger G, Lindner W, Brunner G, Stoschitzky K. Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studies. J Pharm Biomed Anal 1994;12:1537-1545.
6. Chidsey CA, Morselli P, Bianchetti G, Morganti A, Leonetti G, Zanchetti A. Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation 1975;52:313-318.
7. Lehtonen A, Kanto J, Kleimola T. Plasma concentrations of propranolol in patients with essential hypertension. Eur J Clin Pharmacol 1977;11:155-157.
8. Pine M, Favrot L, Smith S, McDonald K, Chidsey CA. Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris. Circulation 1975;52:886-893.
9. Colangelo P, Chandler M, Blouin R, McNamara P. Stereoselective binding of propranolol in the elderly. Br J Clin Pharmacol 1989; 27:519-522.
10. Wu X, Noda A, Noda H, Eto S, Muro H, Ono Y, Inokuchi K. Enantioselective metabolism of propanolol in isolated hepatocytes prepared from untreated, PB- or 3-MC-pretreated rats. J UOEH 2001;23:23-34.
11. Zhou Q, Yao TW, Zeng S. Chiral reversed phase high-performance liquid chromatography for determining propranolol enantiomers in transgenic Chinese hamster CHL cell lines expressing human cytochrome P450. J Biochem Biophys Methods 2002;54:369-376.
12. van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 2005;1:175-185.
13. Petri N, Tannergren C, Rungstad D, Lennernas H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 2004;21:1398-1404.
14. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989;96:736-749.
15. Hunter J, Hirst BH, Simmons NL. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 1993;10:743-749.
16. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 1996;24:634-642.
17. Sabolovic N, Magdalou J, Netter P, Abid A. Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: identification of the UDP-glucuronosyltransferases UGT1A6, 1A3 and 2B7. Life Sci 2000;67:185-196.
18. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 2006;20: 273-282.
19. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, Langguth P. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci 1998;87:757-762.
20. Wang Y, Cao J, Zeng S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J Pharm Pharmacol 2005;57:751-758.
21. Cox DS, Gao H, Raje S, Scott KR, Eddington ND. Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin. Eur J Pharm Biopharm 2001;52:145-150.
22. Hubatsch I, Ragnarsson EG, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2007;2:2111-2119.
23. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Gefroh HA, Devane CL. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 2006;317:850-857.
24. Yamaguchi H, Yano I, Saito H, Inui K. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. Eur J Pharmacol 2001;431:297-303.
25. Kang HJ, Lee SS, Lee CH, Shim JC, Shin HJ, Liu KH, Yoo MA, Shin JG. Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters. Drug Metab Dispos 2006;34:1145-1151.
26. Dickman KG, Hempson SJ, Anderson J, Lippe S, Zhao L, Burakoff R, Shaw RD. Rotavirus alters paracellular permeability and energy metabolism in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol 2000;279:G757-G766.
27. Wang Y, Cao J, Weng JH, Zeng S. Simultaneous determination of quercetin, kaempferol and isorhamnetin accumulated human breast cancer cells, by high-performance liquid chromatography. J Pharm Biomed Anal 2005;39:328-333.
28. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175:880-885.
29. Lu S, Gough AW, Bobrowski WF, Stewart BH. Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes. J Pharm Sci 1996;85:270-273.
30. Muranushi N, Horie K, Masuda K, Hirano K. Characteristics of ceftibuten uptake into Caco-2 cells. Pharm Res 1994;11:1761-1765.
31. Cova E, Laforenza U, Gastaldi G, Sambuy Y, Tritto S, Faelli A, Ventura U. Guanidine transport across the apical and basolateral membranes of human intestinal Caco-2 cells is mediated by two different mechanisms. J Nutr 2002;132:1995-2003.
32. Yoshigae Y, Imai T, Horita A, Matsukane H, Otagiri M. Species differences in stereoselective hydrolase activity in intestinal mucosa. Pharm Res 1998;15:626-631.
33. Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001;4:185-200.
34. Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci 2008;97:712-725.
35. Palmgren JJ, Monkkonen J, Korjamo T, Hassinen A, Auriola S. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm 2006;64:369-378.
36. Tamai I, Ling HY, Timbul SM, Nishikido J, Tsuji A. Stereospecific absorption and degradation of cephalexin. J Pharm Pharmacol 1988;40:320-324.
37. Wenzel U, Thwaites DT, Daniel H. Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter. Br J Pharmacol 1995;116:3021-3027.
38. Ogihara T, Tamai I, Takanaga H, Sai Y, Tsuji A. Stereoselective and carrier-mediated transport of monocarboxylic acids across Caco-2 cells. Pharm Res 1996;13:1828-1832.
39. Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res 1996;13:963-977.
40. Narawa T, Shimizu R, Takano S, Tsuda Y, Ono K, Yamada H, Itoh T. Stereoselectivity of the reduced folate carrier in Caco-2 cells. Chirality 2005;17:444-449.
41. Siccardi D, Kandalaft LE, Gumbleton M, McGuigan C. Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers. J Pharmacol Exp Ther 2003;307:1112-1119.
42. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-79.
43. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ringhydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994;22:909-915.
44. Sten T, Qvisen S, Uutela P, Luukkanen L, Kostiainen R, Finel M. Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab Dispos 2006;34:1488-1494.
45. Pshezhetsky AV, Fedjaev M, Ashmarina L, Mazur A, Budman L, Sinnett D, Labuda D, Beaulieu JF, Menard D, Nifant'ev I, Levy E. Subcellular proteomics of cell differentiation: quantitative analysis of the plasma membrane proteome of Caco-2 cells. Proteomics 2007;7:2201-2215.